Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 3 Carcinoma, Non-Small-Cell Lung 2 Smoldering Multiple Myeloma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myeloid, Acute 1 Carcinoma, Squamous Cell 1

Interventions

Paclitaxel 20 Gemcitabine 16 Dexamethasone 16 Bevacizumab 16 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Fluorouracil 11 Leucovorin 10 Cisplatin 10 pembrolizumab 9 Pemetrexed 9 Epoetin Alfa 9 venetoclax 8 Prednisone 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 atezolizumab 7 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × Maintenance × Clear all

NCT07207824 2025-10-06

HERO

Fudan University

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡